Breast Cancer Screening and Diagnosis Clinical Practice Guidelines in Oncology NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is
Search Results
Breast Cancer Screening and Diagnosis
Therese B. Bevers, Benjamin O. Anderson, Ermelinda Bonaccio, Sandra Buys, Mary B. Daly, Peter J. Dempsey, William B. Farrar, Irving Fleming, Judy E. Garber, Randall E. Harris, Alexandra S. Heerdt, Mark Helvie, John G. Huff, Nazanin Khakpour, Seema A. Khan, Helen Krontiras, Gary Lyman, Elizabeth Rafferty, Sara Shaw, Mary Lou Smith, Theodore N. Tsangaris, Cheryl Williams, and Thomas Yankeelov
Esophageal and Esophagogastric Junction Cancers
Jaffer A. Ajani, James S. Barthel, David J. Bentrem, Thomas A. D'Amico, Prajnan Das, Crystal S. Denlinger, Charles S. Fuchs, Hans Gerdes, Robert E. Glasgow, James A. Hayman, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Lawrence R. Kleinberg, W. Michael Korn, A. Craig Lockhart, Mary F. Mulcahy, Mark B. Orringer, Raymond U. Osarogiagbon, James A. Posey, Aaron R. Sasson, Walter J. Scott, Stephen Shibata, Vivian E. M. Strong, Thomas K. Varghese Jr., Graham Warren, Mary Kay Washington, Christopher Willett, and Cameron D. Wright
Overview Upper gastrointestinal tract cancers originating in the esophagus, esophagogastric junction (EGJ), and stomach constitute a major health problem around the world. An estimated 37,640 new cases of and 25,070 deaths from upper
Counterpoint: Adjuvant Therapy in Stage II Colon Cancer: Pain Not Justified by the Gain
Katherine Van Loon and Alan P. Venook
Adjuvant therapy for colon cancer evolved in an additive fashion. In the 1980s, 5-fluorouracil (5-FU) administered as a daily bolus regimen made the first positive impact of any therapy on colon cancer survival. 1 The ensuing decade of research
Head and Neck Cancers
David G. Pfister, Kie-Kian Ang, David M. Brizel, Barbara A. Burtness, Anthony J. Cmelak, A. Dimitrios Colevas, Frank Dunphy, David W. Eisele, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Bruce H. Haughey, Wesley L. Hicks Jr., Ying J. Hitchcock, Merrill S. Kies, William M. Lydiatt, Ellie Maghami, Renato Martins, Thomas McCaffrey, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, Sandeep Samant, Giuseppe Sanguineti, David E. Schuller, Jatin P. Shah, Sharon Spencer, Andy Trotti III, Randal S. Weber, Gregory T. Wolf, and Frank Worden
NCCN Clinical Practice Guidelines in Oncology for Head and Neck Cancers NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform
Integrating Diversity, Equity, and Inclusion Approaches Into Treatment of Commercial Tobacco Use for Optimal Cancer Care Delivery
The Cancer Center Cessation Initiative Diversity, Equity, and Inclusion Working Group Members
Background Nearly one-third of all cancer-related deaths are attributable to commercial tobacco use. Improvements in tobacco-related cancer incidence, mortality and tobacco cessation, however, have not been equitably experienced across all
Risk of New-Onset Prostate Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity Score–Matched Study
Yan Hiu Athena Lee, Jiandong Zhou, Jeremy Man Ho Hui, Xuejin Liu, Teddy Tai Loy Lee, Kyle Hui, Jeffrey Shi Kai Chan, Abraham Ka Chung Wai, Wing Tak Wong, Tong Liu, Kenrick Ng, Sharen Lee, Edward Christopher Dee, Qingpeng Zhang, and Gary Tse
Background Prostate cancer is the most common cancer diagnosis among male patients, and in 2019 was one of the main causes of death worldwide, with 487,000 deaths. 1 Known risk factors for prostate cancer include family history, ethnicity, and
Management of Metastatic Castration-Resistant Prostate Cancer
Presented by: Sandy Srinivas
Advances in the management of metastatic castration-resistant prostate cancer (mCRPC) include more sophisticated and sensitive imaging modalities that improve cancer detection and staging compared with conventional imaging methods. These methods
Preventing Overdiagnosis and Overtreatment: Just the Next Step in the Evolution of Breast Cancer Care
Rita A. Mukhtar, Jasmine M. Wong, and Laura J. Esserman
is given to how these tools are used. Cancer care is particularly relevant to this issue because of the increasing number of imaging tools, diagnostic molecular tests, and novel therapeutics that are emerging from clinical development and available to
Common Controversies in the Management of Gallbladder Cancer
Chandrakanth Are
Rare in the Western world, gallbladder cancer is a lethal cancer more commonly seen in Eastern countries and some countries in South America. Surgery has the potential to cure most cases of early-stage disease and prolong survival in some advanced
Central Nervous System Cancers
The University of Michigan Comprehensive Cancer Center
The incidence of primary malignant brain tumors is increasing, especially in the elderly, and metastatic disease to the central nervous system (CNS) occurs even more frequently (an incidence about 10 times that of primary brain tumors). In fact, estimates are that 20% to 40% of patients with systemic cancer will develop brain metastases. Primary and metastatic brain tumors are heterogeneous, with varied outcomes and management strategies. This marked heterogeneity means that prognostic features and treatment options must be carefully reviewed for each patient. As these guidelines note, the involvement of an interdisciplinary team is key in the appropriate management of these patients. Important updates to the guidelines include the addition of systemic chemotherapy as a salvage therapy treatment option for local recurrence and limited metastatic lesions and its deletion as an option for multiple metastatic lesions.
For the most recent version of the guidelines, please visit NCCN.org
